Form S-3ASR Intra-Cellular Therapies

Go back to Form S-3ASR Intra-Cellular Therapies

Intra-Cellular Therapies (ITCI) PT Raised to $91 at BofA Securities

April 17, 2024 5:13 AM UTC

BofA Securities analyst Jason Gerberry raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $91.00 (from $82.00) while maintaining a Buy rating.

The analyst comments "This morning, ITCI reported positive Ph3 topline results from its first MDD trial (Study 501) assessing Caplyta as an... More

Intra-Cellular Therapies (ITCI) Files Mixed Shelf

April 16, 2024 4:04 PM UTC

Intra-Cellular Therapies (NASDAQ: ITCI) has filed mixed shelf of:

COMMON STOCK

PREFERRED STOCK

DEBT SECURITIES

WARRANTS

RIGHTS

UNITS

... More